Mr Mathieu Bigois
Chair
Former Managing Partner at Speria AG (Ponthieu Partners), a healthcare-focused advisory firm he co-founded in 2009 in Zug. Until 2019, Mr. Bigois was Venture Partner Europe at Ally Bridge, a $3B Hong Kong-based life sciences fund. He led key deals including the 2017 buyout of KKR’s stake in Galenica and evaluated cross-border investments across biopharma, medtech, aesthetics, and luxury sectors.
He began his career in London with Wasserstein Perella in 1997, later joining healthcare banking teams at Credit Suisse and Citigroup, and served as CFO of DrugAbuse Sciences Inc., a US-French biotech firm. Mr. Bigois has a global network and advises both strategic and financial healthcare clients across developed and select emerging markets (notably CIS, Turkey, MENA, Latin America). His clients include Elan, Aspen, Biogen Idec, Sanofi, Ramsay, Merck Serono, and various private equity and biotech firms.
He holds an MSc in Engineering from Ecole Centrale Paris and an MSc in Finance & Economics from LSE (British Council Scholar).
